Veraxa Biotech Holding AG (NASDAQ:VRXA) Shares Shorted: Short Interest Down 54.3% in October

Veraxa Biotech Holding AG (NASDAQ:VRXA) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 107,383 shares, a decline of 54.3% from the September 30th total of 235,019 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 421,031 shares, the short-interest ratio is currently 0.3 days.

Insider Activity at Veraxa Biotech

In other news, Director Christoph Samuel Ziegler bought 30,000 shares of Veraxa Biotech stock in a transaction dated Tuesday, October 20th. The shares were acquired at an average cost of $1.09 per share, with a total value of $32,700.00. Following the completion of the transaction, the director owned 37,932 shares in the company, valued at approximately $41,345.88. This trade represents a 378.21% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Oliver Baumann bought 50,000 shares of the stock in a transaction dated Thursday, August 27th. The shares were acquired at an average price of $1.50 per share, with a total value of $75,000.00. Following the completion of the purchase, the director directly owned 5,773,618 shares of the company’s stock, valued at approximately $8,660,427. This represents a 0.87% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 95,000 shares of company stock worth $125,333 over the last three months.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research report on Monday, August 31st.

Veraxa Biotech Price Performance

Shares of Veraxa Biotech stock opened at $1.13 on Friday. The stock’s 50 day moving average is $1.29. Veraxa Biotech has a 12-month low of $0.95 and a 12-month high of $27.36.

Veraxa Biotech Company Profile

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.